APO Research
Talk to an analyst

APO RESEARCH · REPORT

Sepsis and Septic Shock Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Sepsis and Septic Shock Treatment Market Outlook and Growth Opportunities 2026

2 January 2026201 pages

Choose your research edition.

Industry ResearchSepsis and Septic Shock Treatment Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Sepsis and Septic Shock Treatment Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Sepsis and Septic Shock Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sepsis and Septic Shock Treatment Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Sepsis and Septic Shock Treatment Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Sepsis and Septic Shock Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Sepsis and Septic Shock Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sepsis and Septic Shock Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sepsis and Septic Shock Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Sepsis and Septic Shock Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Sepsis and Septic Shock Treatment market include TEVA, Johnson & Johnson, Novartis, Pfizer, GlaxoSmithKline, Bayer, AbbVie, Viatris and Shanghai Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Sepsis and Septic Shock Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sepsis and Septic Shock Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sepsis and Septic Shock Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Sepsis and Septic Shock Treatment market.

Sepsis and Septic Shock Treatment Segment by Company

TEVA

Johnson & Johnson

Novartis

Pfizer

GlaxoSmithKline

Bayer

AbbVie

Viatris

Shanghai Pharmaceuticals

NCPC

Merck & Co

INOTREM

Endacea

AtoxBio

Asahi Kasei

Adrenomed

Sepsis and Septic Shock Treatment Segment by Type

Macrolides

Pencillin

Cephalosporin

Others

Sepsis and Septic Shock Treatment Segment by Application

Sepsis

Septic Shock

Sepsis and Septic Shock Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Sepsis and Septic Shock Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Sepsis and Septic Shock Treatment key companies, revenue, market share, and recent developments.

3. To split the Sepsis and Septic Shock Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Sepsis and Septic Shock Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sepsis and Septic Shock Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Sepsis and Septic Shock Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sepsis and Septic Shock Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sepsis and Septic Shock Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sepsis and Septic Shock Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sepsis and Septic Shock Treatment industry.

Chapter 3: Detailed analysis of Sepsis and Septic Shock Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Sepsis and Septic Shock Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Sepsis and Septic Shock Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sepsis and Septic Shock Treatment Industry Trends Table 2. Sepsis and Septic Shock Treatment Industry Drivers Table 3. Sepsis and Septic Shock Treatment Industry Opportunities and Challenges Table 4. Sepsis and Septic Shock Treatment Industry Restraints Table 5. Global Sepsis and Septic Shock Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sepsis and Septic Shock Treatment Revenue Share by Company (2021-2026) Table 7. Global Sepsis and Septic Shock Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Sepsis and Septic Shock Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Sepsis and Septic Shock Treatment Company, Product Type & Application Table 10. Global Sepsis and Septic Shock Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Sepsis and Septic Shock Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Macrolides Table 15. Significant Companies of Pencillin Table 16. Significant Companies of Cephalosporin Table 17. Significant Companies of Others Table 18. Global Sepsis and Septic Shock Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Sepsis and Septic Shock Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Sepsis and Septic Shock Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Sepsis and Septic Shock Treatment Sales Value Share by Type (2021-2026) Table 22. Global Sepsis and Septic Shock Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Sepsis Table 24. Significant Companies of Septic Shock Table 25. Global Sepsis and Septic Shock Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Sepsis and Septic Shock Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Sepsis and Septic Shock Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Sepsis and Septic Shock Treatment Sales Value Share by Application (2021-2026) Table 29. Global Sepsis and Septic Shock Treatment Sales Value Share by Application (2027-2032) Table 30. Global Sepsis and Septic Shock Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Sepsis and Septic Shock Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Sepsis and Septic Shock Treatment Sales Value Share by Region (2021-2026) Table 33. Global Sepsis and Septic Shock Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Sepsis and Septic Shock Treatment Sales Value Share by Region (2027-2032) Table 35. Global Sepsis and Septic Shock Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Sepsis and Septic Shock Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Sepsis and Septic Shock Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global Sepsis and Septic Shock Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Sepsis and Septic Shock Treatment Sales Value Market Share by Country (2027-2032) Table 40. TEVA Company Information Table 41. TEVA Business Overview Table 42. TEVA Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. TEVA Sepsis and Septic Shock Treatment Product Portfolio Table 44. TEVA Recent Development Table 45. Johnson & Johnson Company Information Table 46. Johnson & Johnson Business Overview Table 47. Johnson & Johnson Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Johnson & Johnson Sepsis and Septic Shock Treatment Product Portfolio Table 49. Johnson & Johnson Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis Sepsis and Septic Shock Treatment Product Portfolio Table 54. Novartis Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Pfizer Sepsis and Septic Shock Treatment Product Portfolio Table 59. Pfizer Recent Development Table 60. GlaxoSmithKline Company Information Table 61. GlaxoSmithKline Business Overview Table 62. GlaxoSmithKline Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. GlaxoSmithKline Sepsis and Septic Shock Treatment Product Portfolio Table 64. GlaxoSmithKline Recent Development Table 65. Bayer Company Information Table 66. Bayer Business Overview Table 67. Bayer Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Bayer Sepsis and Septic Shock Treatment Product Portfolio Table 69. Bayer Recent Development Table 70. AbbVie Company Information Table 71. AbbVie Business Overview Table 72. AbbVie Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. AbbVie Sepsis and Septic Shock Treatment Product Portfolio Table 74. AbbVie Recent Development Table 75. Viatris Company Information Table 76. Viatris Business Overview Table 77. Viatris Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Viatris Sepsis and Septic Shock Treatment Product Portfolio Table 79. Viatris Recent Development Table 80. Shanghai Pharmaceuticals Company Information Table 81. Shanghai Pharmaceuticals Business Overview Table 82. Shanghai Pharmaceuticals Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Shanghai Pharmaceuticals Sepsis and Septic Shock Treatment Product Portfolio Table 84. Shanghai Pharmaceuticals Recent Development Table 85. NCPC Company Information Table 86. NCPC Business Overview Table 87. NCPC Sepsis and Septic Shock Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. NCPC Sepsis and Septic Shock Treatment Product Portfolio Table 89. NCPC Recent Development Table 90. Merck & Co Company Information Table 91. Merck & Co Business Overview Table 92. Merck & Co Sepsis and Septic Shock Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Merck & Co Sepsis and Septic Shock Treatment Product Portfolio Table 94. Merck & Co Recent Development Table 95. INOTREM Company Information Table 96. INOTREM Business Overview Table 97. INOTREM Sepsis and Septic Shock Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. INOTREM Sepsis and Septic Shock Treatment Product Portfolio Table 99. INOTREM Recent Development Table 100. Endacea Company Information Table 101. Endacea Business Overview Table 102. Endacea Sepsis and Septic Shock Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Endacea Sepsis and Septic Shock Treatment Product Portfolio Table 104. Endacea Recent Development Table 105. AtoxBio Company Information Table 106. AtoxBio Business Overview Table 107. AtoxBio Sepsis and Septic Shock Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. AtoxBio Sepsis and Septic Shock Treatment Product Portfolio Table 109. AtoxBio Recent Development Table 110. Asahi Kasei Company Information Table 111. Asahi Kasei Business Overview Table 112. Asahi Kasei Sepsis and Septic Shock Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Asahi Kasei Sepsis and Septic Shock Treatment Product Portfolio Table 114. Asahi Kasei Recent Development Table 115. Adrenomed Company Information Table 116. Adrenomed Business Overview Table 117. Adrenomed Sepsis and Septic Shock Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Adrenomed Sepsis and Septic Shock Treatment Product Portfolio Table 119. Adrenomed Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Sepsis and Septic Shock Treatment Product Image Figure 2. Global Sepsis and Septic Shock Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sepsis and Septic Shock Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Sepsis and Septic Shock Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Macrolides Image Figure 8. Pencillin Image Figure 9. Cephalosporin Image Figure 10. Others Image Figure 11. Global Sepsis and Septic Shock Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Sepsis and Septic Shock Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Sepsis and Septic Shock Treatment Sales Value Share by Type (2021-2032) Figure 14. Sepsis Image Figure 15. Septic Shock Image Figure 16. Global Sepsis and Septic Shock Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Sepsis and Septic Shock Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Sepsis and Septic Shock Treatment Sales Value Share by Application (2021-2032) Figure 19. Global Sepsis and Septic Shock Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Sepsis and Septic Shock Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Sepsis and Septic Shock Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America Sepsis and Septic Shock Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Sepsis and Septic Shock Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Sepsis and Septic Shock Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Sepsis and Septic Shock Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Sepsis and Septic Shock Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Sepsis and Septic Shock Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America Sepsis and Septic Shock Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Sepsis and Septic Shock Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Sepsis and Septic Shock Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Macrolides
  • Pencillin
  • Cephalosporin
  • Others
Applications
  • Sepsis
  • Septic Shock
Companies covered
  • TEVA
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AbbVie
  • Viatris
  • Shanghai Pharmaceuticals
  • NCPC
  • Merck & Co
  • INOTREM
  • Endacea
  • AtoxBio
  • Asahi Kasei
  • Adrenomed

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Sepsis and Septic Shock Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Sepsis and Septic Shock Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Sepsis and Septic Shock Treatment Market Dynamics
  1. 2.1 Sepsis and Septic Shock Treatment Industry Trends
  2. 2.2 Sepsis and Septic Shock Treatment Industry Drivers
  3. 2.3 Sepsis and Septic Shock Treatment Industry Opportunities and Challenges
  4. 2.4 Sepsis and Septic Shock Treatment Industry Restraints
3 Sepsis and Septic Shock Treatment Market by Company
  1. 3.1 Global Sepsis and Septic Shock Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Sepsis and Septic Shock Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Sepsis and Septic Shock Treatment Company Ranking (2024-2026)
  4. 3.4 Global Sepsis and Septic Shock Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Sepsis and Septic Shock Treatment Company Product Type and Application
  6. 3.6 Global Sepsis and Septic Shock Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Sepsis and Septic Shock Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Sepsis and Septic Shock Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Sepsis and Septic Shock Treatment Market by Type
  1. 4.1 Sepsis and Septic Shock Treatment Type Introduction
  2. 4.1.1 Macrolides
  3. 4.1.2 Pencillin
  4. 4.1.3 Cephalosporin
  5. 4.1.4 Others
  6. 4.2 Global Sepsis and Septic Shock Treatment Sales Value by Type
  7. 4.2.1 Global Sepsis and Septic Shock Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Sepsis and Septic Shock Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Sepsis and Septic Shock Treatment Sales Value Share by Type (2021-2032)
5 Sepsis and Septic Shock Treatment Market by Application
  1. 5.1 Sepsis and Septic Shock Treatment Application Introduction
  2. 5.1.1 Sepsis
  3. 5.1.2 Septic Shock
  4. 5.2 Global Sepsis and Septic Shock Treatment Sales Value by Application
  5. 5.2.1 Global Sepsis and Septic Shock Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Sepsis and Septic Shock Treatment Sales Value by Application (2021-2032)
  7. 5.2.3 Global Sepsis and Septic Shock Treatment Sales Value Share by Application (2021-2032)
6 Sepsis and Septic Shock Treatment Regional Value Analysis
  1. 6.1 Global Sepsis and Septic Shock Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sepsis and Septic Shock Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Sepsis and Septic Shock Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Sepsis and Septic Shock Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Sepsis and Septic Shock Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Sepsis and Septic Shock Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Sepsis and Septic Shock Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Sepsis and Septic Shock Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Sepsis and Septic Shock Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Sepsis and Septic Shock Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Sepsis and Septic Shock Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Sepsis and Septic Shock Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Sepsis and Septic Shock Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Sepsis and Septic Shock Treatment Sales Value Share by Country, 2025 VS 2032
7 Sepsis and Septic Shock Treatment Country-level Value Analysis
  1. 7.1 Global Sepsis and Septic Shock Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sepsis and Septic Shock Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Sepsis and Septic Shock Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Sepsis and Septic Shock Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Sepsis and Septic Shock Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Sepsis and Septic Shock Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Sepsis and Septic Shock Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 TEVA
  2. 8.1.1 TEVA Company Information
  3. 8.1.2 TEVA Business Overview
  4. 8.1.3 TEVA Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 TEVA Sepsis and Septic Shock Treatment Product Portfolio
  6. 8.1.5 TEVA Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Sepsis and Septic Shock Treatment Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Sepsis and Septic Shock Treatment Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Sepsis and Septic Shock Treatment Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Sepsis and Septic Shock Treatment Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Sepsis and Septic Shock Treatment Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Sepsis and Septic Shock Treatment Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 Viatris
  44. 8.8.1 Viatris Company Information
  45. 8.8.2 Viatris Business Overview
  46. 8.8.3 Viatris Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Viatris Sepsis and Septic Shock Treatment Product Portfolio
  48. 8.8.5 Viatris Recent Developments
  49. 8.9 Shanghai Pharmaceuticals
  50. 8.9.1 Shanghai Pharmaceuticals Company Information
  51. 8.9.2 Shanghai Pharmaceuticals Business Overview
  52. 8.9.3 Shanghai Pharmaceuticals Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Shanghai Pharmaceuticals Sepsis and Septic Shock Treatment Product Portfolio
  54. 8.9.5 Shanghai Pharmaceuticals Recent Developments
  55. 8.10 NCPC
  56. 8.10.1 NCPC Company Information
  57. 8.10.2 NCPC Business Overview
  58. 8.10.3 NCPC Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 NCPC Sepsis and Septic Shock Treatment Product Portfolio
  60. 8.10.5 NCPC Recent Developments
  61. 8.11 Merck & Co
  62. 8.11.1 Merck & Co Company Information
  63. 8.11.2 Merck & Co Business Overview
  64. 8.11.3 Merck & Co Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Merck & Co Sepsis and Septic Shock Treatment Product Portfolio
  66. 8.11.5 Merck & Co Recent Developments
  67. 8.12 INOTREM
  68. 8.12.1 INOTREM Company Information
  69. 8.12.2 INOTREM Business Overview
  70. 8.12.3 INOTREM Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 INOTREM Sepsis and Septic Shock Treatment Product Portfolio
  72. 8.12.5 INOTREM Recent Developments
  73. 8.13 Endacea
  74. 8.13.1 Endacea Company Information
  75. 8.13.2 Endacea Business Overview
  76. 8.13.3 Endacea Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Endacea Sepsis and Septic Shock Treatment Product Portfolio
  78. 8.13.5 Endacea Recent Developments
  79. 8.14 AtoxBio
  80. 8.14.1 AtoxBio Company Information
  81. 8.14.2 AtoxBio Business Overview
  82. 8.14.3 AtoxBio Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AtoxBio Sepsis and Septic Shock Treatment Product Portfolio
  84. 8.14.5 AtoxBio Recent Developments
  85. 8.15 Asahi Kasei
  86. 8.15.1 Asahi Kasei Company Information
  87. 8.15.2 Asahi Kasei Business Overview
  88. 8.15.3 Asahi Kasei Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Asahi Kasei Sepsis and Septic Shock Treatment Product Portfolio
  90. 8.15.5 Asahi Kasei Recent Developments
  91. 8.16 Adrenomed
  92. 8.16.1 Adrenomed Company Information
  93. 8.16.2 Adrenomed Business Overview
  94. 8.16.3 Adrenomed Sepsis and Septic Shock Treatment Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Adrenomed Sepsis and Septic Shock Treatment Product Portfolio
  96. 8.16.5 Adrenomed Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst